Form 4: REGENXBIO Officer Granted Significant Equity Awards

REGENXBIO's Chief Strategy & Legal Officer, Patrick J. Christmas, received significant equity awards, including restricted stock units and stock options, on January 6, 2026.

Summary

• Patrick J. Christmas, Chief Strategy & Legal Officer of REGENXBIO Inc., was granted 73,749 shares of common stock underlying a time-based restricted stock unit (RSU) award on January 6, 2026.
• The RSU award has a vesting schedule where 25% of the shares will vest on January 6, 2027, 2028, 2029, and 2030, contingent on continuous service.
• Additionally, Mr. Christmas was granted stock options to acquire 39,650 shares of common stock with an exercise price of $14.18 per share on January 6, 2026.
• The stock options will vest 25% after 12 months of continuous service, with the remaining balance vesting in equal monthly installments over the 36 months following January 6, 2027.
• The stock options have an expiration date of January 6, 2036.
• Following these transactions, Mr. Christmas beneficially owns 215,367 shares of common stock and 39,650 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event. It is slightly positive as it indicates executive retention and alignment of interests, but does not contain new operational or financial performance data.

Positives

• The equity awards align the executive's interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedules for both RSUs and stock options promote executive retention by requiring continuous service over several years.

Negatives

• The issuance of new equity awards, particularly stock options, can lead to minor dilution for existing shareholders upon vesting and exercise.

Risks

• The value of the equity awards is subject to the future performance of REGENXBIO's stock price, meaning the actual realized value could be lower than the potential value at grant.
• The vesting of these awards is contingent on continuous service, posing a risk to the recipient if employment is terminated before full vesting.

Future Outlook

The equity awards are structured to incentivize Patrick J. Christmas to provide continuous service to REGENXBIO Inc. for several years, aligning his long-term commitment with the company's strategic goals and shareholder value creation.

Industry Context

The granting of restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to attract, retain, and motivate key personnel by linking their compensation to the company's long-term performance and stock value.

Comparison to Industry Standards

• The structure of these equity awards, including a mix of RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation packages observed in comparable biotech companies.
• The vesting periods (e.g., 4-year RSU vesting, 4-year option vesting) are standard for executive retention and long-term incentive plans across the industry.

Stakeholder Impact

• Shareholders: Minor potential for dilution from the new equity awards, but also increased incentive for executive performance.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and compensation philosophy.

Next Steps

• Patrick J. Christmas will continue to provide continuous service to the Issuer to meet the vesting conditions for both the RSU and stock option awards.
• The RSU awards will vest in 25% increments annually on January 6, 2027, 2028, 2029, and 2030.
• The stock options will begin vesting after 12 months of continuous service, with subsequent monthly installments following January 6, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a senior executive as part of their compensation package. Such a transaction is standard practice and does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should consider this as an expected event within the normal course of corporate governance and executive incentive alignment.

Keywords

REGENXBIO, RGNX, Form 4, insider transaction, equity award, restricted stock unit, RSU, stock options, executive compensation, Patrick J. Christmas